CellProtect Nordic Pharmaceuticals AB receives funding from Vinnova

CellProtect Nordic Pharmaceuticals AB has received a 1 MSEK grant from Vinnova, Sweden’s Innovation Agency. The funds will be used to upscale the production of a novel drug candidate CellProtect, an advanced therapy medicinal product (ATMP), for the treatment of multiple myeloma. The project will be conducted in collaboration with Karolinska University Hospital.

The grant has been provided to CellProtect Nordic Pharmaceuticals AB within the program “Competence Centers; Support for SMEs 2018″. Its aim is to stimulate active and sustainable participation of small and medium size enterprises facilitating growth of the Swedish biologics industry.

Moreover, CellProtect Nordic Pharmaceuticals AB and the Karolinska University Hospital, via the Karolinska Cell Therapy Center (KCC) and its production unit Vecura, are partners of the Vinnova Competence Centre for Advanced BioProduction by Continuous Processing (AdBIOPRO). This key competence centre, focusing on manufacturing of emerging potent therapeutic products, is coordinated by the Royal Institute of Technology in Stockholm, and includes a number of industrial partners.

“We are very grateful for the grant for this important work. Upscaling of the production is an imperative step in order to initiate confirmatory clinical trials with CellProtect in patients with multiple myeloma which is a  primary indication for our drug candidate” says Karin Mellström, CEO of CellProtect Nordic Pharmaceuticals AB.

CellProtect Nordic Pharmaceuticals AB participates in the SWElife’s project on Advanced Therapy Medicinal Products (ATMPs)

CellProtect Nordic Pharmaceuticals AB  participates in the SWElife’s project on Advanced Therapy Medicinal Products (ATMPs)

SWElife’sATMP project focuses on business development based on health economics, value-based health care and the available infrastructures within Sweden. The goal is to strengthen Sweden’s position in the international field of ATMPs.

CellProtect Nordic Pharmaceuticals AB  is one of 14 project partners representing both academia and public bodies as well as the private sector. The partners will contribute with their expertise to pave the way for these pharmaceuticals to the patient’s bedside.

Karin Mellström will represent CellProtect Nordic Pharmaceuticals AB  in the coming discussions.

“We are very happy to participate in this work that may have a significant impact on patients with severe, currently incurable, diseases”  says Karin Mellström, CEO of CellProtect Nordic Pharmaceuticals AB 

 Read more about the project on SWElife homepage (Swedish): 

https://swelife.se/2018/11/13/nytt-projekt-greppar-om-de-avancerade-terapilakemedlens-halsoekonomiska-utmaningar/

Agneta Edberg to the Board of CellProtect Nordic Pharmaceuticals AB

Agneta Edberg to the Board of CellProtect Nordic Pharmaceuticals AB

At the Annual General Meeting of CellProtect Nordic Pharmaceuticals AB (‘CPNP’) on April 11, 2018, Agneta Edberg was elected as a new board member.

Agneta Edberg, born 1956, has approximately 25 years of experience from leading positions in life sciences. She has, among other things, been Managing Director of Mylan AB and Svenska Läkemedelsförsäkningen and has also held leading positions in Pfizer, Bactiguard and Cilag (Johnson & Johnson). Agneta has been chairman of Immunicum AB, which is now listed on the Stockholm Stock Exchange’s main market, between 2010 and 2018. She is also chairman of the cell therapy company Idogen, which is listed on Aktietorget. Agneta is a board member of the Vinnova project CAMP, Centre for Advanced Medical Products.

“I am very pleased that we were able to tie Agneta Edberg to CellProtect Nordic Pharmaceuticals. With her experience in immune oncology, cell-based advanced therapies, ATMPs, and from major pharmaceutical companies, Agneta will be an extremely important addition as the company is now entering a new exciting phase in its development” says Lena Degling Wikingsson, CPNP’s chairman.

CPNP has performed a Phase I / II clinical trial in multiple myeloma patients where CellProtect has been studied as an adjunct therapy to autologous stem cell transplantation. The results are very promising, as CellProtect in the clinical trials shows a good safety profile and also gives signals of effect. CellProtect was recently granted orphan drug designation from the European Commission for the treatment of multiple myeloma.

“I’m really looking forward to work with CPNP’s owner and management so that patients in the future will have access to a safe and important therapy” says Agneta Edberg.

In addition, at the annual general meeting, Lena Degling Wikingsson (Chairman), Hans-Gustaf Ljunggren and Gunnar Mattsson were elected as board members.